Blood tests may predict lung cancer return after surgery

NCT ID NCT07476495

Recruiting now Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 100 people with early-stage lung cancer who had surgery. Researchers will measure tumor cells and DNA in their blood to see if these markers can predict if the cancer comes back. The goal is to better understand how lung cancer spreads and improve long-term care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients are at higher risk of recurrence, leading to more personalized follow-up and treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and the findings might not apply to all lung cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCOLOGY & EPIDEMIOLOGY & LUNG CANCER

Contacts and locations

Locations

IRCCS Azienda Ospedaliero-Università di Bologna
RECRUITING

Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.